Red Flags Detected

  • Going Concern (worsened) — Going-concern disclosure persists with runway extended from Q3 2025 to Q1 2027, but substantial doubt remains unresolved despite November 2025 capital raise.
NASDAQ: VRCA Verrica Pharmaceuticals Inc. 10-Q

Verrica raises $49M, extinguishes debt, advances VP-315 to Phase 3 prep; Q1 revenue up 46%

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~2 min read

Key Changes

  • high

    Securities class action certified in March 2026, escalating litigation risk and potential damages exposure beyond individual plaintiff claims.

    Controls & Legal Proceedings verify on EDGAR →
  • high

    Company raised $49M in November 2025 equity offering and fully extinguished $50M OrbiMed debt for $35M cash, eliminating monthly principal payments and covenant restrictions but extending going-concern runway only to Q1 2027.

    MD&A: Liquidity verify on EDGAR →
  • high

    YCANTH launched in Japan (February 2026) following September 2025 regulatory approval; Q1 collaboration revenue jumped to $0.7M from $17K prior year on commercial supply shipments to partner Torii.

    MD&A: Japan Launch verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.

Partner

Trade VRCA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov View full financials on EDGAR ↗

Generated by AI · Jun 10, 2026 10:12 PM